HomeGreater Than Icon
Concord Biotech LtdGreater Than Icon
Concord Biotech Ltd Financials
Company Logo

Concord Biotech Ltd Financial Statement

Concord Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue226.11
Operating Expense134.52
Net Profit58.24
Net Profit Margin25.76
Earning Per Share5.57
EBIDTA91.05
Effective Tax Rate21.17

Concord Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,016.94
Operating Expenses Annual585.38
Operating Profit Annual465.34
Interest Annual2.55
Depreciation51.56
Net Profit Annual304.73
Tax Annual104.46

Concord Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning3.50
Cash Flow from Operations265.47
Cash Flow from Investing-154.61
Cash Flow from Financing-99.21
Cash Flow at the End15.14

Concord Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)45.82
PBIT Margin (%)40.55
PBT Margin (%)27.80
Net PROFIT Margin (%)29.97
Return On Networth / Equity (%)21.63
Return On Networth /Employed (%)28.81
Return On Assets (%)21.28
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)0.71

Concord Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual575.32
Total Current Assets Annual896.23
Non Current Assets Annual803.08
Total Shareholders Funds Annual1,525.25
Total Assets Annual1,699.32

Concord Biotech Ltd Earning Calls

EPS (INR)

Expected

5.70

Reported

5.70

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by -0.13%

Get Your FAQs Right

As of Nov 5, 2024, Concord Biotech Ltd has a market capitalization of 15,922.06 Cr. Value Research classifies it as a Large-Cap company.
Yes, Concord Biotech Ltd is debt-free with a debt-to-equity ratio of 0.01.
In FY 2023 , Concord Biotech Ltd recorded a total revenue of approximately 1,016.94 Cr marking a significant milestone in the company's financial performance.
Concord Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.2% annually, respectively..
Concord Biotech Ltd's current PE ratio is 52.25.
Concord Biotech Ltd's ROCE averaged 24.1% from the FY ending March 2022 to 2024, with a median of 24.5%. It peaked at 26.8% in March 2024, reflecting strong capital efficiency over the period..
Concord Biotech Ltd's latest EBIT is Rs. 411.74 Cr, surpassing the average EBIT of Rs. 327.65 Cr over the 5 years..